Encore Vision Inc., of Fort Worth, Texas, said that the FDA has approved its investigational new drug application for EV06, a topical ophthalmic solution to treat presbyopia, and that the company has since enrolled the first subject into their phase I/II trial of the lipoic acid choline ester compound.